Pharma Equity Group A/S Cl A Asset Resilience Ratio

Latest as of June 2019: 2.24%

Pharma Equity Group A/S Cl A asset resilience ratio. Pharma Equity Group A/S Cl A (PEG) has an Asset Resilience Ratio of 2.24% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pharma Equity Group A/S Cl A (PEG) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Dkr1.72 Million
≈ $269.58K USD Cash + Short-term Investments

Total Assets

Dkr77.09 Million
≈ $12.06 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Pharma Equity Group A/S Cl A (2008–2018)

Asset resilience ratio of Pharma Equity Group A/S Cl A from 2008 to 2018. This chart shows how Pharma Equity Group A/S Cl A's Asset Resilience Ratio has changed over time. Read debt load of Pharma Equity Group A/S Cl A for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Pharma Equity Group A/S Cl A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pharma Equity Group A/S Cl A assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Dkr0.00 0%
Short-term Investments Dkr1.72 Million 2.24%
Total Liquid Assets Dkr1.72 Million 2.24%

Asset Resilience Insights

  • Limited Liquidity: Pharma Equity Group A/S Cl A maintains only 2.24% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Pharma Equity Group A/S Cl A Industry Peers by Asset Resilience Ratio

Compare Pharma Equity Group A/S Cl A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Pharma Equity Group A/S Cl A Asset Resilience Ratio by Year (2008–2018)

Pharma Equity Group A/S Cl A asset resilience ratio by year from 2008 to 2018. The table below shows the annual Asset Resilience Ratio data for Pharma Equity Group A/S Cl A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-09-30 2.13% Dkr1.72 Million
≈ $269.58K
Dkr80.84 Million
≈ $12.65 Million
+1.06pp
2016-09-30 1.07% Dkr1.35 Million
≈ $210.90K
Dkr125.75 Million
≈ $19.67 Million
-0.27pp
2015-09-30 1.34% Dkr1.69 Million
≈ $264.10K
Dkr126.25 Million
≈ $19.75 Million
-5.61pp
2012-09-30 6.95% Dkr35.00 Million
≈ $5.48 Million
Dkr503.85 Million
≈ $78.83 Million
+0.05pp
2011-09-30 6.89% Dkr35.00 Million
≈ $5.48 Million
Dkr507.76 Million
≈ $79.44 Million
-69.48pp
2008-09-30 76.37% Dkr199.84 Million
≈ $31.27 Million
Dkr261.67 Million
≈ $40.94 Million
--
pp = percentage points

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology
Market Cap
$13.60 Million
Dkr86.91 Million DKK
Market Cap Rank
#26122 Global
#120 in Denmark
Share Price
Dkr0.07
Change (1 day)
+3.81%
52-Week Range
Dkr0.07 - Dkr0.12
All Time High
Dkr2.81
About

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more